Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 2/2014

01-06-2014 | Hot Topic

Fat and Bone Interactions

Authors: Sandra Bermeo, Krishanthi Gunaratnam, Gustavo Duque

Published in: Current Osteoporosis Reports | Issue 2/2014

Login to get access

Abstract

Fat and bone have a complicated relationship. Although obesity has been associated with low fracture risk, there is increasing evidence that some of the factors that are released by peripheral fat into the circulation may also have a deleterious effect on bone mass, thus, predisposing to fractures. More importantly, the local interaction between fat and bone within the bone marrow seems to play a significant role in the pathogenesis of age-related bone loss and osteoporosis. This “local interaction” occurs inside the bone marrow and is associated with the autocrine and paracrine release of fatty acids and adipokines, which affect the cells in their vicinity including the osteoblasts, reducing their function and survival. In this review, we explore the particularities of the fat and bone cell interactions within the bone marrow, their significance in the pathogenesis of osteoporosis, and the potential therapeutic applications that regulating marrow fat may have in the near future as a novel pharmacologic treatment for osteoporosis.
Literature
1.
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
2.
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115–37.PubMed
3.
Riggs BL, Khosla S, Melton III LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279–302.PubMedCrossRef
4.
Duque G, Troen BR. Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome. J Am Geriatr Soc. 2008;56:935–41.PubMedCrossRef
5.
Gunaratnam K, Vidal C, Gimble JM, et al. Mechanisms of palmitate-induced lipotoxicity in human osteoblasts. Endocrinology. 2014;155:108–16.PubMedCrossRef
6.
Wauquier F, Philippe C, Leotoing L, et al. The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem. 2013;288:6542–51.PubMedCentralPubMedCrossRef
7.
8.•
Ng A, Duque G. Osteoporosis as a Lipotoxic Disease. IBMS BoneKEy. 2010;7:108–23. Comprehensive review on the mechanisms of lipotoxicity in bone.CrossRef
9.
Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab. 1992;75:779–82.PubMed
10.
Albala C, Yanez M, Devoto E, et al. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996;20:1027–32.PubMed
11.•
Cohen A, Dempster DW, Recker RR, et al. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab. 2013;98:2562–72. Important study looking at the relationship between abdominal fat and bone mass.PubMedCrossRef
12.
Bredella MA, Fazeli PK, Lecka-Czernik B, et al. IGFBP-2 is a negative predictor of cold-induced brown fat and bone mineral density in young non-obese women. Bone. 2013;53:336–9.PubMedCentralPubMedCrossRef
13.
Gilsanz V, Chalfant J, Mo AO, et al. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab. 2009;94:3387–93.PubMedCentralPubMedCrossRef
14.••
Gimble JM, Nuttall ME. The relationship between adipose tissue and bone metabolism. Clin Biochem. 2012;45:874–9. Excellent review on the relationship between adipose tissue and bone.PubMedCrossRef
15.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.PubMedCrossRef
16.
Di Iorgi N, Mo AO, Grimm K, et al. Bone acquisition in healthy young females is reciprocally related to marrow adiposity. J Clin Endocrinol Metab. 2010;95:2977–82.PubMedCentralPubMedCrossRef
17.
Gimble JM, Robinson CE, Wu X, et al. The function of adipocytes in the bone marrow stroma: an update. Bone. 1996;19:421–8.PubMedCrossRef
18.•
Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. J Intern Med. 2012;272:317–29. General overview of the relationship between fat and bone focused on peripheral fat.PubMedCentralPubMedCrossRef
19.
Corre J, Planat-Benard V, Corberand JX, et al. Human bone marrow adipocytes support complete myeloid and lymphoid differentiation from human CD34 cells. Br J Haematol. 2004;127:344–7.PubMedCrossRef
20.•
Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829–34. Excellent review on the mechanisms of mesenchymal stem cell differentiation.PubMedCentralPubMedCrossRef
21.
Si YL, Zhao YL, Hao HJ, et al. MSCs: biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev. 2011;10:93–103.PubMedCrossRef
22.
23.
24.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.PubMedCrossRef
25.••
Boxall SA, Jones E. Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int. 2012;2012:975871. Comprehensive review on the mechanisms of stem cell differentiation.PubMedCentralPubMedCrossRef
26.
Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant. 2013;18:51–8.PubMedCrossRef
27.
28.
29.••
Al-Nbaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013;9:32–43. Good review on the biology of mesenchymal stem cells.PubMedCentralPubMedCrossRef
30.
31.
Stolzing A, Jones E, McGonagle D, et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129:163–73.PubMedCrossRef
32.
Hammoudi TM, Rivet CA, Kemp ML, et al. Three-dimensional in vitro tri-culture platform to investigate effects of crosstalk between mesenchymal stem cells, osteoblasts, and adipocytes. Tissue Eng A. 2012;18:1686–97.CrossRef
33.
Lu Z, Roohani-Esfahani S-I, Wang G, et al. Bone biomimetic microenvironment induces osteogenic differentiation of adipose tissue-derived mesenchymal stem cells. Nanomedicine. 2012;8:507–15.PubMedCrossRef
34.
Elbaz A, Wu X, Rivas D, et al. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010;14:982–91.PubMedCrossRef
35.
Rosen CJ, Ackert-Bicknell C, Rodriguez JP, et al. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr. 2009;19:109–24.PubMedCentralPubMedCrossRef
36.
Kang S, Bennett CN, Gerin I, et al. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem. 2007;282:14515–24.PubMedCrossRef
37.
Kurra S, Siris E. Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab Res Rev. 2011;27:430–5.PubMedCrossRef
38.
Taxel P, Kaneko H, Lee SK, et al. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int. 2008;19:193–9.PubMedCrossRef
39.
40.
Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379:261–6.PubMedCrossRef
41.
Gaur T, Lengner CJ, Hovhannisyan H, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005;280:33132–40.PubMedCrossRef
42.
Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7:885–96.PubMedCrossRef
43.•
Takada I, Kouzmenko AP, Kato S. Wnt and PPAR gamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol. 2009;5:442–7. Excellent review on the role of Wnt and PPAR gamma in osteoblast and adipocyte differentiation.PubMedCrossRef
44.
Komori T. Signaling networks in RUNX2-dependent bone development. J Cell Biochem. 2011;112:750–5.PubMedCrossRef
45.
Yavropoulou MP, Yovos JG. The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones. 2007;6:279–94.PubMedCrossRef
46.
47.
48.
Chang MK, Kramer I, Keller H, et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering Wnt signaling activity. J Bone Miner Res. 2014;29:29–42.PubMedCrossRef
49.
Frost M, Andersen T, Gossiel F, et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res. 2011;26:1721–8.PubMedCrossRef
50.•
Cawthorn WP, Bree AJ, Yao Y, et al. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone. 2012;50:477–89. Relevant information on the role of Wnts in osteoblastogenesis.PubMedCentralPubMedCrossRef
51.
Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12:722–34.PubMedCrossRef
52.
Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24:1651–61.PubMedCrossRef
53.•
Duque G, Li W, Yeo LS, et al. Attenuated anabolic response to exercise in lamin A/C haploinsufficient mice. Bone. 2011;49:412–8. Initial report on the role of the proteins of the nuclear envelope in osteoblastogenesis.PubMedCrossRef
54.
Piemonte S, Romagnoli E, Bratengeier C, et al. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest. 2012;35:866–8.PubMed
55.
Korvala J, Löija M, Mäkitie O, et al. Rare variations in WNT3A and DKK1 may predispose carriers to primary osteoporosis. Eur J Med Genet. 2012;55:515–9.PubMedCrossRef
56.
Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934–45.PubMedCrossRef
57.
Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.PubMedCrossRef
58.
Glantschnig H, Hampton RA, Lu P, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285:40135–47.PubMedCentralPubMedCrossRef
59.••
Canalis E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9:575–83. Excellent overview of the role of Wnt signaling in osteoporosis.PubMedCrossRef
60.
Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009;433:1–7.PubMedCrossRef
61.••
Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272–88. Comprehensive assessment of the role of BMPs in bone formation.PubMedCentralPubMedCrossRef
62.
Piek E, Sleumer LS, van Someren EP, et al. Osteo-transcriptomics of human mesenchymal stem cells: accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis. Bone. 2010;46:613–27.PubMedCrossRef
63.•
Duque G, Li W, Vidal C, et al. Pharmacological inhibition of PPARgamma increases osteoblastogenesis and bone mass in male C57BL/6 mice. J Bone Miner Res. 2013;28:639–48. Most recent report on the therapeutic applications of PPAR gamma inhibition in osteoporosis.PubMedCrossRef
64.
Swift J, Ivanovska IL, Buxboim A, et al. Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science. 2013;341:1240104.PubMedCrossRef
65.
Crisp M, Burke B. The nuclear envelope as an integrator of nuclear and cytoplasmic architecture. FEBS Lett. 2008;582:2023–32.PubMedCrossRef
66.
67.
Akter R, Rivas D, Geneau G, et al. Effect of lamin A/C knockdown on osteoblast differentiation and function. J Bone Miner Res. 2009;24:283–93.PubMedCrossRef
68.
Rauner M, Sipos W, Goettsch C, et al. Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. J Bone Miner Res. 2009;24:78–86.PubMedCrossRef
69.
Duque G, Rivas D. Age-related changes in lamin A/C expression in the osteoarticular system: laminopathies as a potential new aging mechanism. Mech Ageing Dev. 2006;127:378–83.PubMedCrossRef
70.
Rivas D, Li W, Akter R, et al. Accelerated features of age-related bone loss in zmpste24 metalloproteinase-deficient mice. J Gerontol A Biol Sci Med Sci. 2009;64:1015–24.PubMedCrossRef
71.
72.
Kumeta M, Yoshimura SH, Hejna J, et al. Nucleocytoplasmic shuttling of cytoskeletal proteins: molecular mechanism and biological significance. Int J Cell Biol. 2012;2012:494902.PubMedCentralPubMedCrossRef
73.
Tilgner K, Wojciechowicz K, Jahoda C, et al. Dynamic complexes of A-type lamins and emerin influence adipogenic capacity of the cell via nucleocytoplasmic distribution of beta-catenin. J Cell Sci. 2009;122:401–13.PubMedCentralPubMedCrossRef
74.
75.
Vidal C, Bermeo S, Li W, et al. Interferon gamma inhibits adipogenesis in vitro and prevents marrow fat infiltration in oophorectomized mice. Stem Cells. 2012;30:1042–8.PubMedCrossRef
76.
Fournier C, Perrier A, Thomas M, et al. Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells. Bone. 2012;50:499–509.PubMedCrossRef
77.•
Driessler F, Baldock PA. Hypothalamic regulation of bone. J Mol Endocrinol. 2010;45:175–81. Original evidence on hypothalamic regulation of bone.PubMedCrossRef
78.
Yadav VK, Oury F, Tanaka KF, et al. Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications. J Exp Med. 2011;208:41–52.PubMedCentralPubMedCrossRef
79.
Mason JJ, Williams BO. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos. 2010;2010:460120.
80.
Inose H, Zhou B, Yadav VK, et al. Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res. 2011;26:2002–11.PubMedCrossRef
81.
Confavreux CB. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. 2011;79 Suppl 121:S14–9.CrossRef
82.
Chen X, Tian HM, Yu XJ. Bone delivers its energy information to fat and islets through osteocalcin. Orthop Surg. 2012;4:114–7.PubMedCrossRef
83.
84.•
Verma S, Rajaratnam JH, Denton J, et al. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol. 2002;55:693–8. Original paper demonstrating the inverse relationship between marrow fat and bone mass in humans.PubMedCentralPubMedCrossRef
85.
Jilka RL, Weinstein RS, Parfitt AM, et al. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007;22:1492–501.PubMedCrossRef
86.
Meunier P, Aaron J, Edouard C, et al. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971;80:147–54.PubMedCrossRef
87.
Wehrli FW, Hopkins JA, Hwang SN, et al. Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry. Radiology. 2000;217:527–38.PubMedCrossRef
88.
Kim JE, Ahn MW, Baek SH, et al. AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast. Bone. 2008;43:394–404.PubMedCrossRef
89.
Maurin AC, Chavassieux PM, Frappart L, et al. Influence of mature adipocytes on osteoblast proliferation in human primary co-cultures. Bone. 2000;26:485–9.PubMedCrossRef
90.
Gasparrini M, Rivas D, Elbaz A, et al. Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL/6 J mice. Exp Gerontol. 2009;44:613–8.PubMedCrossRef
91.
92.
Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signaling: diseases and therapies. Nat Rev Genet. 2004;5:691–701.PubMedCrossRef
93.
Tong J, Li W, Vidal C, et al. Lamin A/C deficiency is associated with fat infiltration of muscle and bone. Mech Ageing Dev. 2011;132:552–9.PubMedCrossRef
94.
Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta. 2007;1771:1082–93.PubMedCrossRef
95.
Goto T, Kim Y-I, Takahashi N, et al. Natural compounds regulate energy metabolism by the modulating the activity of lipid-sensing nuclear receptors. Mol Nutr Food Res. 2013;57:20–33.PubMedCrossRef
96.
Duque G, Huang DC, Macoritto M, et al. Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis. Stem Cells. 2009;27:550–8.PubMedCrossRef
97.
Duque G, Huang DC, Dion N, et al. Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res. 2011;26:1472–83.PubMedCrossRef
98.
Schmid B, Rippmann JF, Tadayyon M, et al. Inhibition of fatty acid synthase prevents preadipocyte differentiation. Biochem Biophys Res Commun. 2005;328:1073–82.PubMedCrossRef
Metadata
Title
Fat and Bone Interactions
Authors
Sandra Bermeo
Krishanthi Gunaratnam
Gustavo Duque
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 2/2014
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0199-y

Other articles of this Issue 2/2014

Current Osteoporosis Reports 2/2014 Go to the issue

Hot Topic

Clinical Considerations of Regenerative Medicine in Osteoporosis

Biomechanics (M Silva and P Zysset, Section Editors)

Ultrasound to Assess Bone Quality

INVITED COMMENTARY

Bone Density Testing: Science, the Media, and Patient Care

Muscle and Bone (L Bonewald and M Harrick, Section Editors)

Endocrine Crosstalk Between Muscle and Bone

Biomechanics (M Silva and P Zysset, Section Editors)

Diabetes, Collagen, and Bone Quality

Biomechanics (M Silva and P Zysset, Section Editors)

Atypical Femoral Fractures, Bisphosphonates, and Mechanical Stress